Schneider Eugene 4

What Happened
Eugene Schneider, EVP and Chief Clinical Development Officer at Ionis Pharmaceuticals (IONS), had 11,991 performance-based restricted stock units (PRSUs) vest on Jan 29, 2026 (reported as an award). The next day (Jan 30, 2026) he sold 6,179 shares in open-market transactions at a weighted-average price of $83.45, generating approximately $515,630 in proceeds. The award entry shows $0 acquisition price because these were vested PRSUs (not a cash purchase).

Key Details

• Transactions: Award/vesting of 11,991 shares (2026-01-29); open-market sale of 6,179 shares (2026-01-30).
• Sale price: weighted average $83.45 per share (individual sale prices ranged $83.32–$83.48). Proceeds ≈ $515,630.
• Net change from these transactions: +5,812 shares (11,991 vested − 6,179 sold). Total shares owned after the transactions are not provided in the excerpt.
• Footnote highlights: The vested PRSUs were from a Jan 18, 2023 grant and vested at 167.27% of target based on relative total shareholder return vs. peers (payout range 0%–200%). The filer can provide a breakdown of shares sold at each price within the stated range on request.
• Filing timeliness: Form filed 2026-02-02 for transactions on Jan 29–30, 2026; this filing is within normal Section 16 reporting timing.

Context

• These transactions reflect vesting of performance-based equity and a subsequent open-market sale of a portion of the vested shares. Awards/vests are compensation events; subsequent sales are commonly used to cover taxes or diversify and do not, by themselves, indicate management sentiment.